Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH
dc.contributor.author | Zumsteg, Zachary S. | |
dc.contributor.author | Chen, Zinan | |
dc.contributor.author | Howard, Lauren E. | |
dc.contributor.author | Amling, Christopher L. | |
dc.contributor.author | Aronson, William J. | |
dc.contributor.author | Cooperberg, Matthew R. | |
dc.contributor.author | Kane, Christopher J. | |
dc.contributor.author | Terris, Martha K. | |
dc.contributor.author | Spratt, Daniel E. | |
dc.contributor.author | Sandler, Howard M. | |
dc.contributor.author | Freedland, Stephen J. | |
dc.date.accessioned | 2017-11-13T16:41:07Z | |
dc.date.available | 2019-02-01T19:56:26Z | en |
dc.date.issued | 2017-12 | |
dc.identifier.citation | Zumsteg, Zachary S.; Chen, Zinan; Howard, Lauren E.; Amling, Christopher L.; Aronson, William J.; Cooperberg, Matthew R.; Kane, Christopher J.; Terris, Martha K.; Spratt, Daniel E.; Sandler, Howard M.; Freedland, Stephen J. (2017). "Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH." The Prostate 77(16): 1592-1600. | |
dc.identifier.issn | 0270-4137 | |
dc.identifier.issn | 1097-0045 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/139104 | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | prostate cancer | |
dc.subject.other | risk stratification | |
dc.subject.other | unfavorable intermediate risk | |
dc.subject.other | very high‐risk prostate cancer | |
dc.title | Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/139104/1/pros23436_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/139104/2/pros23436.pdf | |
dc.identifier.doi | 10.1002/pros.23436 | |
dc.identifier.source | The Prostate | |
dc.identifier.citedreference | Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014; 12: 686 – 718. | |
dc.identifier.citedreference | Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016; 69: 428 – 435. | |
dc.identifier.citedreference | Joniau S, Briganti A, Gontero P, et al. Stratification of high‐risk prostate cancer into prognostic categories: a European multi‐institutional study. Eur Urol. 2015; 67: 157 – 164. | |
dc.identifier.citedreference | Muralidhar V, Chen MH, Reznor G, et al. Definition and validation of “favorable high‐risk prostate cancer”: implications for personalizing treatment of radiation‐managed patients. Int J Radiat Oncol Biol Phys. 2015; 93: 828 – 835. | |
dc.identifier.citedreference | Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate‐risk prostate cancer patients undergoing dose‐escalated external‐beam radiation therapy. Eur Urol. 2013; 64: 895 – 902. | |
dc.identifier.citedreference | Keane FK, Chen MH, Zhang D, et al. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate‐risk disease. Cancer. 2014; 120: 1787 – 1793. | |
dc.identifier.citedreference | Zumsteg ZS, Zelefsky MJ, Woo KM, et al. Unification of favourable intermediate‐, unfavourable intermediate‐, and very high‐risk stratification criteria for prostate cancer. BJU Int. 2017. https://doi.org/10.1111/bju.13903 [Epub ahead of print]. | |
dc.identifier.citedreference | Huang J, Vicini FA, Williams SG, et al. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer ? Int J Radiat Oncol Biol Phys. 2012; 83: 1141 – 1148. | |
dc.identifier.citedreference | D’Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer‐specific mortality for patients with low or favorable intermediate‐risk disease. J Clin Oncol. 2004; 22: 3726 – 3732. | |
dc.identifier.citedreference | Zumsteg ZS, Zelefsky MJ. Short‐term androgen deprivation therapy for patients with intermediate‐risk prostate cancer undergoing dose‐escalated radiotherapy: the standard of care ? Lancet Oncol. 2012; 13: e259 – e269. | |
dc.identifier.citedreference | Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203 – 213. | |
dc.identifier.citedreference | Klotz L, Vesprini D, Sethukavalan P, et al. Long‐term follow‐up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015; 33: 272 – 277. | |
dc.identifier.citedreference | Sundi D, Wang VM, Pierorazio PM, et al. Very‐high‐risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis. 2014; 17: 57 – 63. | |
dc.identifier.citedreference | Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration‐resistant prostate cancer. Clin Cancer Res. 2014; 20: 2846 – 2850. | |
dc.identifier.citedreference | Zumsteg ZS, Daskivich TJ, Sandler TJ. Salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy. J Clin Oncol. 2016. pii: JCO692509. [Epub ahead of print]. | |
dc.identifier.citedreference | Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA. 2015; 314: 80 – 82. | |
dc.identifier.citedreference | Zumsteg ZS, Chen Z, Howard LE, et al. Number of unfavorable intermediate‐risk factors predicts pathologic upstaging and prostate cancer‐specific mortality following radical prostatectomy: results from the SEARCH database. Prostate. 2017; 77: 154 – 163. | |
dc.identifier.citedreference | Raldow AC, Zhang D, Chen MH, et al. Risk group and death from prostate cancer: implications for active surveillance in men with favorable intermediate‐risk prostate cancer. JAMA Oncol. 2015; 1: 334 – 340. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.